P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone
Jean-Luc Harousseau,Antonio Palumbo,Paul G. Richardson,Rudolf Schlag,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Michel Delforge,Rik Schots,Michele Cavo,Anatoly Golenkov,Mieczysław Komarnicki,Maria-Victoria Mateos,Andrew Cakana,Kevin Liu,William Deraedt,Helgi van de Velde,Jesús F. San Miguel +17 more
TL;DR: Assessment of the differential prognostic impact of best response on time-to-event parameters in VISTA and the impact of timing of CR on outcome in patients receiving VMP finds significant benefit was seen for CR and PR vs no response by EBMT criteria for all four parameters, including OS.
Journal ArticleDOI
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Noopur Raje,Edward A. Faber,Paul G. Richardson,Gary J. Schiller,Raymond J. Hohl,Adam D. Cohen,Andres Forero,Susan P. Carpenter,Tuan S. Nguyen,Ilaria Conti,Christopher Kaiser,Damien M. Cronier,James E. Wooldridge,Kenneth C. Anderson +13 more
TL;DR: A dose of 100 mg tabalumab in combination with bortezomib was well tolerated and active and is currently under further investigation.
Journal ArticleDOI
Therapeutic intent of proton pump inhibitor prescription among elderly nonsteroidal anti-inflammatory drug users.
TL;DR: The use of proton pump inhibitors in clinical practice has increased dramatically and the number of PPI’s prescribed has increased significantly.
Journal ArticleDOI
Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)
Paul G. Richardson,Joseph R. Mikhael,Saad Z. Usmani,Noopur Raje,William I. Bensinger,Frank Campana,Lei Gao,Franck Dubin,Claudine Wack,Kenneth C. Anderson +9 more
TL;DR: In this paper, the authors reported the preliminary results of an ongoing Phase Ib dose-escalation study of ISA plus pomalidomide (Pom) and dexamethasone (Dex) in patients with relapsed and refractory multiple myeloma (RRMM) (NCT02283775).
Journal ArticleDOI
Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)
Jesús F. San Miguel,Pieter Sonneveld,Robert Z. Orlowski,Philippe Moreau,Laura Rosiñol,Javid Moslehi,Edward A. Faber,Peter M. Voorhees,Loreta Marquez,Avinash Desai,Helgi van de Velde,Jennifer Elliott,Hongliang Shi,Edward Dow,Nishith K. Jobanputra,Dixie-Lee Esseltine,Liviu Niculescu,Kenneth C. Anderson,Sagar Lonial,Paul G. Richardson +19 more
TL;DR: A retrospective analysis of the risk of heart failure associated with Btz in phase 2 and 3 MM studies leading to regulatory approvals in the US and EU found Btz was associated with a low rate of grade ≥3 heart failure in both the newly diagnosed and relapsed/refractory pts.